Diabetology International

, Volume 7, Issue 4, pp 404–412 | Cite as

A comparison of IDeg + IAsp versus IDet + IAsp in subjects with type 1 diabetes: subgroup analysis of Japanese subjects

  • Y. Ono
  • T. Nishida
  • J. Hyllested-Winge
  • H. Seino
  • T. Sasaki
Original Article



Efficacy and safety were compared between insulin degludec (IDeg) once daily (OD) in combination with mealtime insulin aspart (IAsp) and insulin detemir (IDet) OD or twice daily (BID) in combination with mealtime IAsp in Japanese subjects with type 1 diabetes mellitus (T1DM).

Materials and methods

This was a post hoc analysis of a multinational, controlled, open-label, parallel-group, treat-to-target trial that randomised adults [aged ≥18 years (≥20 years for Japan)] with T1DM for ≥12 months to basal IDeg OD (n = 124) or IDet (n = 62), both with mealtime bolus IAsp. The IDet dosing was adjusted to BID if required at ≥8 weeks.


The estimated mean change in HbA1c from baseline to week 26 (the primary outcome measure) was −1.03 % in the IDeg + IAsp group and −0.94 % in the IDet + IAsp group (mean estimated treatment difference [ETD] −0.09; 95 % confidence interval [CI] −0.29, 0.10). Significantly greater reductions in fasting plasma glucose were observed in the IDeg + IAsp group (mean ETD −39.36 mg/dL; 95 % CI −56.04, −22.68). Both groups had similar rates of confirmed hypoglycaemia (59.9 and 59.2 per patient-year of exposure [PYE] with IDeg + IAsp and IDet + IAsp, respectively). Rates of nocturnal confirmed hypoglycaemia were significantly lower with IDeg + IAsp than with IDet + IAsp (5.2 vs 9.5 episodes per PYE; estimated ratio 0.48; 95 % CI 0.31, 0.75). Adverse event profiles were similar.


The findings were consistent with those of the global trial population. IDeg + IAsp may represent an improvement on current standard treatments for Japanese patients with T1DM.


Type 1 diabetes mellitus Insulin Bolus treatment Japanese 



Medical writing assistance was provided by apothecom scopemedical, UK, and funded by Novo Nordisk.

Compliance with ethical standards

Conflict of interest

Y. Ono has received grants from the Advanced Clinical Research Organization of Japan. T. Nishida is an employee of Novo Nordisk. J. Hyllested-Winge is an employee and shareholder in Novo Nordisk. H. Seino has received honoraria from Astellas, Eli Lilly, Novartis, Sanofi, Shionogi, Boehringer Ingelheim and Mitsubishi Tanabe. He has also received research grants from GSK, Sanofi, Novo Nordisk and Mitsubishi Tanabe Pharma. T. Sasaki has no conflicts to declare.


  1. 1.
    Kawasaki E, Matsuura N, Eguchi K. Type 1 diabetes in Japan. Diabetologia. 2006;49:828–36.CrossRefPubMedGoogle Scholar
  2. 2.
    Park Y. Why is type 1 diabetes uncommon in Asia? Ann NY Acad Sci. 2006;1079:31–40.CrossRefPubMedGoogle Scholar
  3. 3.
    Nathan DM. DCCT/EDIC Research Group. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 years: overview. Diabetes Care. 2014;37:9–16.Google Scholar
  4. 4.
    Lachin JM, Orchard TJ, Nathan DM. DCCT/EDIC Research Group. Update on cardiovascular outcomes at 30 years of The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Care. 2014;37:39–43.Google Scholar
  5. 5.
    Gubitosi-Klug RA. DCCT/EDIC Research Group. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 years: summary and future directions. Diabetes Care. 2014;37:44–9.Google Scholar
  6. 6.
    Chiang JL, Kirkman MS, Laffel LMB, Peters AL. Type 1 diabetes sourcebook authors. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care. 2014;37:2034–54.CrossRefPubMedGoogle Scholar
  7. 7.
  8. 8.
    Kobayashi M, Yamazaki K, Hirao K, Oishi M, Kanatsuka A, Yamauchi M, et al. The status of diabetes control and antidiabetic drug therapy in Japan—a cross-sectional survey of 17,000 patients with diabetes mellitus (JDDM 1). Diabetes Res Clin Pract. 2006;73:198–204.Google Scholar
  9. 9.
    Kanatsuka A, Kawai K, Hirao K, Oishi M, Takagi H, Kobayashi M, et al. Actual usage and clinical effectiveness of insulin preparations in patients with type 1 diabetes mellitus in Japan: CoDiC-based analysis of clinical data obtained at multiple institutions (JDDM 3). Diabetes Res Clin Pract. 2006;72:277–83.Google Scholar
  10. 10.
    Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger P-M. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med J Br Diabet Assoc. 2012;29:682–9.CrossRefGoogle Scholar
  11. 11.
    Kurtzhals P, Heise T, Strauss H, Bottcher SG, Granhall C, Haahr H, et al. Multi-hexamer formation is the underlying basis for the ultra-long glucose-lowering effect of insulin degludec. Diabetologia. 2011;54:S426.Google Scholar
  12. 12.
    Heise T, Hovelmann U, Nosek L, Bottcher S, Granhall C, Haahr H. Insulin degludec has a two-fold longer half-life and a more consistent pharmacokinetic profile compared with insulin glargine. 2012. Accessed May 2015.
  13. 13.
    Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012;14:859–64.CrossRefPubMedGoogle Scholar
  14. 14.
    Novo Nordisk. Tresiba®: product information. 2012. Accessed May 2015.
  15. 15.
    Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379:1489–97.CrossRefPubMedGoogle Scholar
  16. 16.
    Davies MJ, Gross JL, Ono Y, Sasaki T, Bantwal G, Gall MA, et al. Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial. Diabetes Obes Metab. 2014;16:922–30.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Food and Drug Administration. Diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention (draft guidance). 2008. Accessed May 2015.
  18. 18.
    Bartley PC, Bogoev M, Larsen J, Philotheou A. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Diabet Med J Br Diabet Assoc. 2008;25:442–9.Google Scholar
  19. 19.
    Mathieu C, Hollander P, Miranda-Palma B, Cooper J, Franek E, Russell-Jones D, et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab. 2013;98:1154–62.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Ratner RE, Gough SCL, Mathieu C, Del Prato S, Bode B, Mersebach H, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab. 2013;15:175–84.CrossRefPubMedGoogle Scholar
  21. 21.
    Iwamoto Y, Clauson P, Nishida T, Kaku K. Insulin degludec in Japanese patients with type 1 diabetes mellitus: a randomized controlled trial. J Diabetes Investig. 2013;4:62–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Birkeland KI, Home PD, Wendisch U, Ratner RE, Johansen T, Endahl LA, et al. Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care. 2011;3(34):661–5.Google Scholar
  23. 23.
    Hirsch IB, Bode B, Courreges J-P, Dykiel P, Franek E, Hermansen K, et al. Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial. Diabetes Care. 2012;35:2174–81.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Bode BW, Buse JB, Fisher M, Garg SK, Marre M, Merker L, et al. Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trial. Diabet Med J Br Diabet Assoc. 2013;30:1293–7.Google Scholar

Copyright information

© The Japan Diabetes Society 2016

Authors and Affiliations

  • Y. Ono
    • 1
  • T. Nishida
    • 2
  • J. Hyllested-Winge
    • 2
  • H. Seino
    • 3
  • T. Sasaki
    • 4
  1. 1.Yuri Ono Clinic, Diabetes, Internal MedicineSapporoJapan
  2. 2.Novo Nordisk Pharma LtdTokyoJapan
  3. 3.Seino Internal Medicine ClinicFukushimaJapan
  4. 4.Sasaki Hospital Internal MedicineHokkaidoJapan

Personalised recommendations